<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors and play a central role in insulin sensitivity, <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism, and <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Both PPARalpha and -gamma are expressed in the kidney, and their <z:chebi fb="4" ids="48705">agonists</z:chebi> exhibit renoprotective effects in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>In the present studies, we investigated the effect of the PPARalpha/gamma dual <z:chebi fb="4" ids="48705">agonist</z:chebi> tesaglitazar on diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> in type 2 diabetic db/db mice </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment of db/db mice with tesaglitazar for 3 months significantly lowered fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> and homeostasis model assessment of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> levels but had little effect on body weight, <z:e sem="disease" ids="C0028754" disease_type="Disease or Syndrome" abbrv="">adiposity</z:e>, or cardiac function </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment with tesaglitazar was associated with reduced plasma insulin and total <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels and increased plasma adiponectin levels </plain></SENT>
<SENT sid="5" pm="."><plain>Notably, tesaglitazar markedly attenuated <z:mp ids='MP_0002871'>albuminuria</z:mp> and significantly lowered glomerulofibrosis, collagen deposition, and transforming growth factor-beta1 expression in renal tissues of db/db mice </plain></SENT>
<SENT sid="6" pm="."><plain>In cultured mesangial cells and proximal tubule cells, where both PPARalpha and -gamma were expressed, tesaglitazar treatment abolished high <z:chebi fb="105" ids="17234">glucose</z:chebi>-induced total collagen protein production and type I and IV collagen gene expression </plain></SENT>
<SENT sid="7" pm="."><plain>Collectively, tesaglitazar treatment not only improved <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, glycemic control, and <z:chebi fb="23" ids="18059">lipid</z:chebi> profile but also markedly attenuated <z:mp ids='MP_0002871'>albuminuria</z:mp> and <z:mp ids='MP_0011377'>renal glomerular fibrosis</z:mp> in db/db mice </plain></SENT>
<SENT sid="8" pm="."><plain>These findings support the utility of dual PPARalpha/gamma <z:chebi fb="4" ids="48705">agonists</z:chebi> in treating type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
</text></document>